Please login to the form below

Not currently logged in


This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

Roche in "unprecedented" launch period for new medicines

Roche in

Gazyva's gains came despite increased competition in the CLL market from drugs such as AbbVie/Johnson &Johnson's Imbruvica (ibrutinib) and Gilead Science's Zydelig (idelalisib) and a failed trial

Latest news

More from news
Approximately 4 fully matching, plus 25 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Pharma Marketing Summit: From ”why” to ”how” in multichannel communications
For the first time we’re sharing our observations of pharma conferences — kicking off with our delegates’ views of the Annual Pharma Marketing Summit in Berlin last month....
Access to orphan drugs for rare cancers in EU28
Revisiting Instagram for pharma
In pharma, Instagram usage is increasing because it offers so many benefits to engage with patients and HCPs...